Sepracor's experimental epilepsy drug (Stedesa) proceeds to FDA review. STEDESA, a new chemical entity, is a novel voltage-gated sodium channel blocker. STEDESA has been studied in three Phase …
Today’s Top Three in Pharma 040909
Genentech pulls Raptiva from the U.S. market. Risk/benefit ratio got too dicey. AstraZeneca gets a limited approval for Seroquel as add-on treatment for depression. Layoffs + executive raises. Works …
Today’s Top Three in Pharma 021709
J&J tops out Barron's list of Best Companies, for 2nd year in a row. Generic competitors awake to Sepracor's Lunesta - Drug maker Sepracor Inc. said two competitors have filed applications to …
Today’s Top Three in Pharma 012909
Sepracor cutting 20% of its workforce. Ouch. Sepracor Inc, maker of the Lunesta sleep drug, said on Wednesday it would cut about 20 percent of its workforce, or 530 jobs, in an effort to save some …
August ’08 Pharma News
The Xa factor: not looking so promising for Pfizer and Bristol - Bristol-Myers Squibb and Pfizer's apixaban blood clot preventer raised rates of bleeding in a 6-month study but showed some encouraging …
Pharma News 11_2
Barren pipelines abound - the drug drought of pharma. Schering's promising clot drug continues to do well in trials. Amgen and Roche go another round in court over anemia drugs - this round to …